Cargando…
Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation
Artesunate (ART) has been indicated as a candidate drug for hepatocellular carcinoma (HCC). Glucosylceramidase (GBA) is required for autophagic degradation. Whether ART regulates autophagic flux by targeting GBA in HCC remains to be defined. Herein, our data demonstrated that the dramatic overexpres...
Autores principales: | Chen, Wenjia, Ma, Zhaochen, Yu, Lingxiang, MAO, Xia, Ma, Nan, Guo, Xiaodong, Yin, Xiaoli, Jiang, Funeng, Wang, Qian, Wang, Jigang, Fang, Mingliang, Lin, Na, Zhang, Yanqiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535011/ https://www.ncbi.nlm.nih.gov/pubmed/36123535 http://dx.doi.org/10.1038/s12276-022-00780-6 |
Ejemplares similares
-
Aberrant regulation of LncRNA TUG1-microRNA-328-3p-SRSF9 mRNA Axis in hepatocellular carcinoma: a promising target for prognosis and therapy
por: Liu, Yudong, et al.
Publicado: (2022) -
Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis
por: Drews, Kelly, et al.
Publicado: (2019) -
Enzyme kinetics and inhibition parameters of human leukocyte glucosylceramidase
por: Karatas, Mesut, et al.
Publicado: (2020) -
Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
por: McDowell, Anthony, et al.
Publicado: (2021) -
Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease
por: Yildiz, Yildiz, et al.
Publicado: (2013)